Current investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating significant effects in treating obesity and type 2 condition. Initial evidence suggest a novel action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/